LMNGF News and Press, BioVaxys Technology

BioVaxys Announces New Chief Financial Officer Canada NewsWire VANCOUVER, BC , Sept. 8, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that Mr. Craig Loverock ha...

BioVaxys announces completed synthesis of its Pan-Sarbecovirus Vaccine candidate and launch of in vivo animal study Canada NewsWire VANCOUVER, BC , Sept. 6, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys...

BIOVAXYS ANNOUNCES COMPLETED DEBT SETTLEMENT Canada NewsWire VANCOUVER, B.C. , Aug. 2, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") further to its news release dated July 4, 2022 , Bi...

Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process Development Canada NewsWire VANCOUVER, BC , June 15, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVA...

Bio-Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU Clinical Study Canada NewsWire VANCOUVER, BC , June 8, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), anno...

BioVaxys and The Ohio State University Progress Pan-Sarbecovirus Vaccine Research Program Canada NewsWire Pan-Sarbecovirus Vaccines Identified by WHO as a Critical Need VANCOUVER, BC , June 3, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (F...

BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement Canada NewsWire VANCOUVER, BC , May 18, 2022 /CNW/ -- BioVaxys Technology Corp. ( CSE: BIOV; FRA: 5LB; ...

International Patent Application Filed for Cervical Cancer Vaccine Canada NewsWire VANCOUVER, BC , May 2, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has continued to exp...

BIOVAXYS ANNOUNCES APPOINTMENT TO BOARD OF DIRECTORS Canada NewsWire VANCOUVER , BC , April 29, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF ) ("BioVaxys" or the "Company") is pleased to announce that Mr. Anthony Dutton...

BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction Canada NewsWire VANCOUVER, BC , April 25, 2022 /CNW/ -- BioVaxys Technology Corp. ( CSE: BIOV, FRA:5LB, OTCQB:BVAXF) ( "BioVaxys"...